What is the main difference in clinical evidence?

Tesamorelin has randomized VAT-outcome trials in adults with HIV and lipodystrophy. The cited GHRP-6 studies in healthy volunteers measured acute hormone or sleep responses, not fat-loss benefit.

Are both compounds FDA approved?

Tesamorelin has a labeled FDA indication for excess abdominal fat in adults with HIV and lipodystrophy. No FDA-approved GHRP-6 product is established by the cited FDA record.

Does a growth hormone response show that GHRP-6 has the same benefits?

No. A short-term hormone response does not establish a clinical outcome, long-term safety or equivalence to tesamorelin.

Tesamorelin vs GHRP-6: Clinical Evidence

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Different evidence questions

Tesamorelin is a growth hormone-releasing hormone analog. Its labeled indication is reduction of excess abdominal fat in adults with HIV and lipodystrophy. The pivotal randomized trial measured VAT, while FDA labeling says the drug is not for weight-loss management and that long-term cardiovascular safety has not been established. FDA prescribing information; Falutz et al., 2007, PMID 18057338.

GHRP-6 is a growth hormone-releasing peptide studied as a secretagogue. In a small study of healthy men, repeated exposure increased growth hormone, ACTH and cortisol during the observation night. Another study in nine healthy men investigated how endogenous GHRH affects the acute GH response to GHRP-6. Those hormone findings do not test VAT reduction or patient benefit. Frieboes et al., 1995, PMID 7617137; GHRP-6 physiology study, PMID 9543138.

Question	Tesamorelin	GHRP-6
Evidence grade for the cited outcome	High for VAT reduction in indicated adults	Low for clinical benefit; acute hormone responses are documented
Studied population here	Adults with HIV and excess abdominal fat	Small healthy-volunteer physiology studies
FDA status	Approved for the specific labeled indication	No FDA-approved GHRP-6 product established in the cited FDA record
Long-term safety	Cardiovascular safety not established by labeling	Not established by the cited acute studies

An FDA enforcement record identifies GHRP-6 among compounded substances that did not meet the cited conditions for compounding exemptions. That record does not confer product approval or establish safety for any marketed preparation. FDA warning letter, 2020.

No cited study compares clinical outcomes between these compounds or establishes the safety or benefit of combining them. Claims about appetite, cortisol, side-effect frequency or insurance cannot be ranked across these different studies.

Educational comparison only; not medical advice.

Tesamorelin vs GHRP-6

Tesamorelin

GHRP-6

Different evidence questions

View Full Dossiers

Stay Updated on Peptide Comparisons